Variable | Pre-ICNB group (n = 38) | Post-ICNB group (n = 43) | P value |
---|---|---|---|
Median Age (y) | 58.08 ± 9.02 | 60.16 ± 8.50 | 0.288 |
BMI (kg/m2) | 22.99 ± 3.16 | 23.89 ± 3.0 | 0.195 |
Gender (n, %) | Â | Â | 0.494 |
 Male | 17 (44.7%) | 16 (37.2%) |  |
 Female | 21 (55.3%) | 27 (62.8%) |  |
Comorbidity (n, %) | Â | Â | Â |
 Hypertension | 1(2.6%) | 8 (18.6%) | 0.023 |
 Diabetes | 1 (2.6%) | 4 (9.3%) | 0.216 |
 Neurological disease | 1 (2.6%) | 0 | 0.287 |
 Pulmonary disease | 1 (2.6%) | 1(2.3%) | 0.930 |
ASA score (n, %) | Â | Â | 0.051 |
 I | 34 (87%) | 31 (72.1%) |  |
 II | 4 (13%) | 12 (27.9%) |  |
Revised cardiac risk index (n, %) | Â | Â | 0.287 |
 1 point | 37 (97.4%) | 43 (100%) |  |
 2 points | 1 (2.6%) | 0 |  |
LVEF value% | 71.02 ± 6.80 | 69.95 ± 5.38 | 0.434 |
Pulmonary function tests (%) | Â | Â | Â |
 FVC % predicted | 101.28 ± 13.80 | 102.83 ± 23.37 | 0.715 |
 FEV1% predicted | 93.42 ± 15.38 | 99.04 ± 18.59 | 0.149 |
Surgical location (n, %) | Â | Â | 0.195 |
 Upper lobe | 19 (50%) | 27 (62.8%) |  |
 Middle lobe | 5 (13.2%) | 6 (14.0%) |  |
 Lower lobe | 14 (36.8%) | 10 (23.3%) |  |
Surgical site (n, %) | Â | Â | 0.176 |
 Left side | 18 (47.4%) | 14 (32.6%) |  |
 Right side | 20 (52.6%) | 29 (67.4%) |  |
Tumor size (mm) | 22.18 ± 7.40 | 20.21 ± 10.65 | 0.342 |